Alpha Tau Medical’s (DRTS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Alpha Tau Medical (NASDAQ:DRTS) in a report released on Wednesday, Benzinga reports. HC Wainwright currently has a $9.00 target price on the stock.

Separately, Piper Sandler reiterated an “overweight” rating and issued a $7.00 price objective on shares of Alpha Tau Medical in a research report on Thursday, August 15th.

Alpha Tau Medical Stock Down 0.9 %

Shares of DRTS opened at $2.20 on Wednesday. The stock has a fifty day simple moving average of $2.28 and a two-hundred day simple moving average of $2.34. The company has a quick ratio of 11.60, a current ratio of 11.66 and a debt-to-equity ratio of 0.07. The company has a market capitalization of $153.28 million, a PE ratio of -5.37 and a beta of 0.77. Alpha Tau Medical has a 52-week low of $1.75 and a 52-week high of $3.65.

Alpha Tau Medical (NASDAQ:DRTS) last issued its earnings results on Wednesday, August 14th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02. As a group, equities analysts forecast that Alpha Tau Medical will post -0.48 EPS for the current year.

Institutional Investors Weigh In On Alpha Tau Medical

A number of institutional investors have recently made changes to their positions in DRTS. Levin Capital Strategies L.P. boosted its position in shares of Alpha Tau Medical by 2.6% during the 1st quarter. Levin Capital Strategies L.P. now owns 338,764 shares of the company’s stock worth $999,000 after purchasing an additional 8,641 shares during the period. Caprock Group LLC purchased a new position in shares of Alpha Tau Medical during the second quarter worth $59,000. Aptus Capital Advisors LLC grew its stake in shares of Alpha Tau Medical by 83.7% in the second quarter. Aptus Capital Advisors LLC now owns 21,945 shares of the company’s stock valued at $56,000 after buying an additional 10,000 shares in the last quarter. Financial Guidance Group Inc. raised its holdings in shares of Alpha Tau Medical by 83.7% in the 2nd quarter. Financial Guidance Group Inc. now owns 21,945 shares of the company’s stock valued at $56,000 after buying an additional 10,000 shares during the period. Finally, USAdvisors Wealth Management LLC acquired a new position in Alpha Tau Medical during the 1st quarter worth about $30,000. 2.65% of the stock is currently owned by institutional investors and hedge funds.

About Alpha Tau Medical

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.